Mark G. Kris

100.9k total citations · 39 hit papers
661 papers, 62.4k citations indexed

About

Mark G. Kris is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Mark G. Kris has authored 661 papers receiving a total of 62.4k indexed citations (citations by other indexed papers that have themselves been cited), including 443 papers in Pulmonary and Respiratory Medicine, 386 papers in Oncology and 131 papers in Molecular Biology. Recurrent topics in Mark G. Kris's work include Lung Cancer Treatments and Mutations (398 papers), Lung Cancer Research Studies (196 papers) and Lung Cancer Diagnosis and Treatment (152 papers). Mark G. Kris is often cited by papers focused on Lung Cancer Treatments and Mutations (398 papers), Lung Cancer Research Studies (196 papers) and Lung Cancer Diagnosis and Treatment (152 papers). Mark G. Kris collaborates with scholars based in United States, Japan and United Kingdom. Mark G. Kris's co-authors include Vincent A. Miller, Gregory J. Riely, William Pao, Maureen F. Zakowski, Marc Ladanyi, Maria E. Arcila, Valerie W. Rusch, Harold Varmus, Richard J. Gralla and Camelia S. Sima and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Mark G. Kris

646 papers receiving 60.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

2004 3.5k citations William Pao, Vincent A. Miller et al. profile →
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

2005 2.8k citations William Pao, Vincent A. Miller et al. profile →
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

2003 2.1k citations Mark G. Kris et al. profile →
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers

2013 1.9k citations Helena A. Yu, Maria E. Arcila et al. Clinical Cancer Research profile →
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial

2015 1.7k citations Mark G. Kris et al. Journal of Clinical Oncology profile →
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

2005 1.2k citations William Pao, Gregory J. Riely et al. profile →
TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

2005 1.2k citations Mark G. Kris, Vincent A. Miller et al. Journal of Clinical Oncology profile →
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

2000 1.1k citations Vincent A. Miller, Mark G. Kris et al. Journal of Clinical Oncology profile →
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

1991 1.1k citations Mark G. Kris et al. profile →
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

2011 827 citations Mark G. Kris et al. Journal of Clinical Oncology profile →
Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases

2011 757 citations Gregory J. Riely, Mark G. Kris et al. profile →
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

2000 665 citations Maureen F. Zakowski, Mark G. Kris et al. profile →
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

2006 664 citations Marissa N. Balak, Yixuan Gong et al. Clinical Cancer Research profile →
ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

2002 646 citations Mark G. Kris et al. Journal of Clinical Oncology profile →
Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

2009 644 citations William Pao, Gregory J. Riely et al. Journal of Clinical Oncology profile →
Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer

2004 628 citations Vincent A. Miller, Mark G. Kris et al. Journal of Clinical Oncology profile →
Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

2006 623 citations Gregory J. Riely, William Pao et al. Clinical Cancer Research profile →
Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

1998 606 citations Mark G. Kris et al. Journal of Clinical Oncology profile →
Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis

2014 601 citations Jamie E. Chaft, Mark G. Kris et al. profile →
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation

2012 555 citations Maria E. Arcila, Elisa de Stanchina et al. Cancer Discovery profile →
Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials

2005 518 citations Mark G. Kris et al. Journal of Clinical Oncology profile →
American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006

2006 516 citations Mark G. Kris et al. Journal of Clinical Oncology profile →
Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations

2011 503 citations Paul K. Paik, Maria E. Arcila et al. Journal of Clinical Oncology profile →
Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS -Mutant Cancers

2012 493 citations Snjezana Doğan, Ronglai Shen et al. Clinical Cancer Research profile →
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

2010 485 citations Geoffrey R. Oxnard, Maria E. Arcila et al. Clinical Cancer Research profile →
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines

1999 483 citations Mark G. Kris et al. Journal of Clinical Oncology profile →
Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes

2009 480 citations Mark G. Kris et al. profile →
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

2011 476 citations Maria E. Arcila, Geoffrey R. Oxnard et al. Clinical Cancer Research profile →
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint

2014 416 citations Matthew D. Hellmann, Jamie E. Chaft et al. profile →
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

2017 397 citations Mark G. Kris et al. Journal of Clinical Oncology profile →
Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 ( HER2 ) Tyrosine Kinase Mutations in Lung Adenocarcinomas

2012 366 citations Maria E. Arcila, Jamie E. Chaft et al. Clinical Cancer Research profile →
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

2013 350 citations Jyoti D. Patel, Sylvia Adams et al. Journal of Clinical Oncology profile →
EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

2013 348 citations Maria E. Arcila, Khédoudja Nafa et al. Molecular Cancer Therapeutics profile →
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

2016 327 citations Alexander Drilon, Natasha Rekhtman et al. profile →
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden

2019 289 citations Ryma Benayed, Michael Offin et al. Clinical Cancer Research profile →
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

2019 271 citations Kathryn C. Arbour, Hira Rizvi et al. profile →
Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update

2017 235 citations Mark G. Kris, Jamie E. Chaft et al. Journal of Clinical Oncology profile →
Antiemetics: ASCO Guideline Update

2020 224 citations Mark G. Kris et al. Journal of Clinical Oncology profile →
Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer

2021 222 citations Jamie E. Chaft, Christopher G. Azzoli et al. profile →

Peers

Countries citing papers authored by Mark G. Kris

Since Specialization

Citations

This map shows the geographic impact of Mark G. Kris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark G. Kris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark G. Kris more than expected).

Fields of papers citing papers by Mark G. Kris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark G. Kris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark G. Kris. The network helps show where Mark G. Kris may publish in the future.

Co-authorship network of co-authors of Mark G. Kris

This figure shows the co-authorship network connecting the top 25 collaborators of Mark G. Kris. A scholar is included among the top collaborators of Mark G. Kris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark G. Kris. Mark G. Kris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden breakdown → 2019 ·Clinical Cancer Research ·Ryma Benayed, Michael Offin, Kerry Mullaney, Purvil Sukhadia, Kelly Rios, Patrice Desmeules, Ryan Ptashkin, Helen Won, Jason C. Chang, Darragh Halpenny, Alison M. Schram, Charles M. Rudin, David M. Hyman, Maria E. Arcila, Michael F. Berger, Ahmet Zehir, Mark G. Kris, Alexander Drilon, Marc Ladanyi	289
2	Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR -Mutant Lung Cancers 2018 ·Clinical Cancer Research ·Michael Offin, Hira Rizvi, Megan Tenet, Ai Ni, Francisco Sánchez-Vega, Bob T. Li, Alexander Drilon, Mark G. Kris, Charles M. Rudin, Nikolaus Schultz, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely, Helena A. Yu, Matthew D. Hellmann	230
3	Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer 2018 ·Clinical Cancer Research ·Ken Suzawa, Michael Offin, Daniel Lu, (unknown), Morana Vojnic, Roger S. Smith, Joshua K. Sabari, Huichun Tai, Marissa S. Mattar, Inna Khodos, Elisa de Stanchina, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, William W. Lockwood, Alexander Drilon, Marc Ladanyi, Romel Somwar	83
4	Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance 2018 ·Clinical Cancer Research ·Helena A. Yu, Ken Suzawa, Emmet Jordan, Ahmet Zehir, Ai Ni, Hyunjae R. Kim, Mark G. Kris, Matthew D. Hellmann, Bob T. Li, Romel Somwar, David B. Solit, Michael F. Berger, Maria E. Arcila, Gregory J. Riely, Marc Ladanyi	188
5	Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS -Mutant Non–Small Cell Lung Cancer 2017 ·Clinical Cancer Research ·Kathryn C. Arbour, (unknown), Hyunjae R. Kim, Jordan Dienstag, Helena A. Yu, Francisco Sánchez-Vega, Piro Lito, Michael F. Berger, David B. Solit, Matthew D. Hellmann, Mark G. Kris, Charles M. Rudin, Ai Ni, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely	317
6	Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases 2015 ·Cancer Discovery ·Paul K. Paik, Ronglai Shen, Helen Won, Natasha Rekhtman, Lu Wang, Camelia S. Sima, Arshi Arora, Venkatraman Seshan, Marc Ladanyi, Michael F. Berger, Mark G. Kris	111
7	EGFR Kinase Domain Duplication ( EGFR -KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib 2015 ·Cancer Discovery ·Jean‐Nicolas Gallant, Jonathan H. Sheehan, Timothy M. Shaver, Mark Bailey, Doron Lipson, Raghu Chandramohan, Monica Red Brewer, Sally J. York, Mark G. Kris, Jennifer A. Pietenpol, Marc Ladanyi, Vincent A. Miller, Siraj M. Ali, Jens Meiler, Christine M. Lovly	81
8	MAP2K1 ( MEK1 ) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking 2014 ·Clinical Cancer Research ·Maria E. Arcila, Alexander Drilon, Brooke E. Sylvester, Christine M. Lovly, Laetitia Borsu, Boris Reva, Mark G. Kris, David B. Solit, Marc Ladanyi	106
9	Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR / KRA S and Presence of PIK3CA / AKT1 Mutations 2012 ·Clinical Cancer Research ·Natasha Rekhtman, Paul K. Paik, Maria E. Arcila, Laura J. Tafe, Geoffrey R. Oxnard, André L. Moreira, William D. Travis, Maureen F. Zakowski, Mark G. Kris, Marc Ladanyi	289
10	Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker 2012 ·Clinical Cancer Research ·M. Catherine Pietanza, Kyuichi Kadota, Kety Huberman, Camelia S. Sima, John J. Fiore, (unknown), William D. Travis, Adriana Heguy, Michelle S. Ginsberg, Andrei I. Holodny, Timothy A. Chan, Naiyer A. Rizvi, Christopher G. Azzoli, Gregory J. Riely, Mark G. Kris, Lee M. Krug	122
11	Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS -Mutant Cancers breakdown → 2012 ·Clinical Cancer Research ·Snjezana Doğan, Ronglai Shen, Daphne Ang, Melissa L. Johnson, Sandra P. D’Angelo, Paul K. Paik, Edyta B. Brzostowski, Gregory J. Riely, Mark G. Kris, Maureen F. Zakowski, Marc Ladanyi	493
12	Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions 2012 ·Clinical Cancer Research ·Yoshiyuki Suehara, Maria E. Arcila, Lu Wang, Adnan Hasanovic, Daphne Ang, Tatsuo Ito, (unknown), Alexander Drilon, Udayan Guha, Valerie W. Rusch, Mark G. Kris, Maureen F. Zakowski, Naiyer A. Rizvi, Raya Khanin, Marc Ladanyi	132
13	Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling 2011 ·Molecular Cancer Therapeutics ·Jamie E. Chaft, Maria E. Arcila, Paul K. Paik, Christopher Lau, Gregory J. Riely, M. Catherine Pietanza, Maureen F. Zakowski, Valerie W. Rusch, Camelia S. Sima, Marc Ladanyi, Mark G. Kris	162
14	Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations breakdown → 2011 ·Journal of Clinical Oncology ·Paul K. Paik, Maria E. Arcila, Michael Fara, Camelia S. Sima, Vincent A. Miller, Mark G. Kris, Marc Ladanyi, Gregory J. Riely	503
15	EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma 2011 ·Clinical Cancer Research ·Mai He, Marzia Capelletti, Khédoudja Nafa, Cai‐Hong Yun, Maria E. Arcila, Vincent A. Miller, Michelle S. Ginsberg, Binsheng Zhao, Mark G. Kris, Michael J. Eck, Pasi A. Jänne, Marc Ladanyi, Geoffrey R. Oxnard	109
16	Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology 2011 ·Journal of Clinical Oncology ·Nicholas J. Vogelzang, (unknown), Sylvia Adams, Carol Aghajanian, Susan M. Chang, ZoAnn E. Dreyer, Pasi A. Jänne, Andrew H. Ko, (unknown), Olatoyosi Odenike, Jyoti D. Patel, Bruce J. Roth, Wolfram E. Samlowski, Andrew D. Seidman, William D. Tap, Jennifer S. Temel, Jamie H. Von Roenn, Mark G. Kris	68
17	Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes 2011 ·Journal of Clinical Oncology ·Geoffrey R. Oxnard, Binsheng Zhao, Camelia S. Sima, Michelle S. Ginsberg, Leonard P. James, Robert A. Lefkowitz, Pingzhen Guo, Mark G. Kris, Lawrence H. Schwartz, Gregory J. Riely	118
18	Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report 2010 ·Clinical Cancer Research ·Nicolas Girard, Emil Lou, Christopher G. Azzoli, (unknown), Mark E. Robson, (unknown), Irene Orlow, Yasushi Yatabe, Khédoudja Nafa, Marc Ladanyi, Agnès Viale, Mark G. Kris, Gregory J. Riely, Vincent A. Miller, Robert J. Klein, Keitaro Matsuo, William Pao	70
19	Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation breakdown → 2010 ·Clinical Cancer Research ·Geoffrey R. Oxnard, Maria E. Arcila, Camelia S. Sima, Gregory J. Riely, Juliann Chmielecki, Mark G. Kris, William Pao, Marc Ladanyi, Vincent A. Miller	485
20	Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors breakdown → 2006 ·Clinical Cancer Research ·Marissa N. Balak, Yixuan Gong, Gregory J. Riely, Romel Somwar, Allan R. Li, Maureen F. Zakowski, Anne C. Chiang, Guangli Yang, Ouathek Ouerfelli, Mark G. Kris, Marc Ladanyi, Vincent A. Miller, William Pao	664

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact